One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study.
Angiotensin converting-enzyme inhibition (ACEI) is a widely accepted treatment during established renal diseases and beneficial effects have also been reported in IgA nephropathy (IgAN). Immunosuppression with myco-phenolate mofetil (MMF) has recently been introduced in the treatment of immune-mediated renal diseases showing promising results. Preliminary clinical reports are also suggestive that MMF is effective in severe forms of IgAN. We propose a randomised prospective trial aimed to compare long-term renal survival of early IgAN in the course of ACEI therapy with or without MMF immunosuppression.
Dal Canton
Antonio
A
Unit of Nephrology, Dialysis and Transplantation, IRCCS Policlinico San Matteo and University of Pavia, Pavia. dalcanton@mbox.medit.it
Amore
Amore
A
Barbano
Giancarlo
G
Coppo
Rosanna
R
Emma
Francesco
F
Grandaliano
Giuseppe
G
Klersy
Catherine
C
Perfumo
Francesco
F
Rizzoni
Gianfranco
G
Schena
Francesco Paolo
FP
Sepe
Vincenzo
V
D000293:Adolescent; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D002648:Child; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005922:Glomerulonephritis, IGA / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid